Psyence Biomed Provides Progress Update on PsyLabs E.U. Good Manufacturing Practices (GMP) Certified Active Pharmaceutical Ingredient (API) DevelopmentGlobeNewsWire • 10/17/24
Psyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence BiomedicalGlobeNewsWire • 10/14/24
Psyence Biomed Provides Update on Previously Announced Acquisition of ClairvoyantGlobeNewsWire • 10/04/24
Psyence Group's NASDAQ-Listed Associate, Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data MilestonesGlobeNewsWire • 09/18/24
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative CareGlobeNewsWire • 09/16/24
Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data MilestonesGlobeNewsWire • 09/16/24
Psyence Biomedical Ltd. Announces Receipt of Staff Delisting Determination from NasdaqGlobeNewsWire • 09/13/24
Psyence Biomed Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative CareGlobeNewsWire • 09/09/24
Psyence Biomed Announces the Signing of a Conditional Binding Term Sheet for the Acquisition of Psilocybin-Based Drug Developer ClairvoyantGlobeNewsWire • 09/06/24
Psyence Biomed Announces Registration Statement on Form F-1 for Up to $25 Million Equity Line of Credit with White Lion Capital, LLC, Declared Effective by SECGlobeNewsWire • 08/30/24
Psyence Biomed to Present at the H.C. Wainwright 26th Annual Global Investment Conference, September 9th-11th, 2024GlobeNewsWire • 08/27/24
Optimi Health and Psyence Biomedical Sign Non-Binding Letter of Intent to Advance Global Psilocybin Drug DevelopmentNewsfile Corp • 08/13/24
Psyence Biomed Enters Into $25 Million Common Stock Purchase Agreement with White Lion Capital, LLCGlobeNewsWire • 07/31/24
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb TrialGlobeNewsWire • 07/26/24
Psyence Biomed Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb TrialGlobeNewsWire • 07/24/24
Psyence Biomedical Ltd. Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyGlobeNewsWire • 07/04/24
Psyence Biomed to Participate in the A.G.P. Virtual Healthcare Company ShowcaseGlobeNewsWire • 05/17/24
Psyence Biomed Announces Phase IIb Clinical Trial Listing on the Australian New Zealand Clinical Trials Registry (ANZCTR)GlobeNewsWire • 04/17/24
Psyence Group's NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin TrialGlobeNewsWire • 04/16/24
Psyence Biomed Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin TrialGlobeNewsWire • 04/08/24
Psyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical BusinessGlobeNewsWire • 03/26/24
Psyence Biomedical Welcomes Results of a Recent Study Highlighting Benefits of Nature Derived Psilocybin Vs. Synthetic PsilocybinGlobeNewsWire • 03/18/24